Clinical MedicineUpdated Aug 6, 2026Version v1
Reviewed milestones, validation shifts, standards, datasets, and debates linked to public evidence.
Evidence from Cancer Discovery indicates that Identified LRRC15+ CAFs in pancreatic cancer that surround tumor islets. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 4 papers in the same timeline signal.
Evidence from Nucleic Acids Research indicates that Integrates single-cell transcriptomic profiles from nearly 2 million cells across 76 tumor datasets and 27 cancer types. This is tracked as a standard because it changes how Personalized cancer vaccines is understood, validated, or applied.
Evidence from Molecular Cancer indicates that No obvious adverse events were observed during neoantigen vaccinations. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Proceedings of the National Academy of Sciences indicates that An LN-targeting LNP (113-O12B) showed increased and specific expression in LNs compared to a standard LNP. This is tracked as a standard because it changes how Personalized cancer vaccines is understood, validated, or applied.
Evidence from JCI Insight indicates that Vaccines targeting both MHCI- and MHCII-specific neoantigens (PancVAX2) improved tumor growth control and survival in mice. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 5 papers in the same timeline signal.
Evidence from Science Advances indicates that LPP-formulated mRNA vaccines induced robust neoantigen-specific CD8+ T cell responses in murine tumor models. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 6 papers in the same timeline signal.
Evidence from Nano Trends indicates that Nanocarriers improve mRNA stability, cellular uptake, and antigen expression. This is tracked as a standard because it changes how Personalized cancer vaccines is understood, validated, or applied.
Evidence from ACS Nano indicates that RGO-PEG nanosheets efficiently deliver neoantigens and adjuvants to lymph nodes. This is tracked as a breakthrough because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Journal for ImmunoTherapy of Cancer indicates that TIGIT is upregulated on immune cells and binds to CD155 and CD112, regulating T and NK cell-mediated tumor recognition. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 3 papers in the same timeline signal.
Evidence from Drug Design Development and Therapy indicates that CpG2018B effectively stimulates type II interferons and cytokine production via TLR9 pathways. This is tracked as a commercial because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from OncoImmunology indicates that EVX-01 demonstrated a short manufacturing time (48-55 days), enabling treatment initiation within 60 days. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 2 papers in the same timeline signal.
Evidence from Scientific Reports indicates that Identified 62 potential neoantigens and three key candidates (TTK, EZH2, KIF4A) for CRC immunotherapy. This is tracked as a clinical because it changes how Personalized cancer vaccines is understood, validated, or applied. It is supported by 4 papers in the same timeline signal.